Oct 4, 2015 by Brian Orelli, PhDKidney Cancer Drug Boxing MatchBristol-Myers Squibb and Exelixis slug it out against Novartis.
Oct 3, 2015 by Brian Orelli, PhDSarepta's Less-Than-Perfect DataGive the drugmaker a pass on its historical control data.
Oct 1, 2015 by Brian Orelli, PhDWhy Illumina Fell TodayAn analyst downgrades the maker of DNA sequencers.
Sep 30, 2015 by Brian Orelli, PhDThe Duchenne Muscular Dystrophy Patent Battle ContinuesIt's far from over, though.
Sep 29, 2015 by Brian Orelli, PhDWhy Sequenom Tumbled TodayAnalysts and investors are unimpressed with the company's plans for a turnaround.
Sep 25, 2015 by Brian Orelli, PhDWhy Sequenom Fell TodayLowered guidance hits the genetic-test company.
Sep 21, 2015 by Brian Orelli, PhDWhy Juno Therapeutics Fell 11% TodayInvestors are spooked about drug pricing.
Sep 21, 2015 by Brian Orelli, PhDWhy Sequenom Slid More Than 15% TodayInvestors get spooked about a leadership change at the diagnostic test company.
Sep 18, 2015 by Brian Orelli, PhDWhy Hasn't Orexigen Launched Its Obesity Drug in Europe Yet?O partner, partner! Wherefore art thou partner?
Sep 17, 2015 by Brian Orelli, PhDWhy Sequenom Jumped 14% TodayUnitedHealthcare agrees to cover Sequenom's diagnostic tests.
Sep 16, 2015 by Brian Orelli, PhDGW Pharmaceuticals' Schizophrenic Marijuana Drug DataRead between the press-release headlines.
Sep 15, 2015 by Brian Orelli, PhDFighting Superbugs: 2 Stocks You Need to KnowDrug resistance is a big problem.
Sep 14, 2015 by Brian Orelli, PhD3 Clinical Trials to Watch As Bluebird Bio Rounds Out 2015Circle Dec. 5-8 on your calendar.
Sep 10, 2015 by Brian Orelli, PhD2 Questions Investors Need to Ask About Biogen's Latest DealThe biotech giant had other options.
Sep 5, 2015 by Brian Orelli, PhDTechnical Analysis for the Long-Term InvestorProfit from the "Little Trigger, Big Homecoming" buy signal.
Sep 4, 2015 by Brian Orelli, PhDPCSK9 Drugs Are Here (and Way Over There)As the first generation of the cholesterol-lowering drugs hits the market, investors should already be looking at the next-generation products.
Aug 27, 2015 by Brian Orelli, PhDThe Duchenne Muscular Dystrophy Race Is OnSarepta Therapeutics and BioMarin now have drugs under FDA review.
Aug 25, 2015 by Brian Orelli, PhDWhy Shares of Celldex Therapeutics, Inc. Soared on TuesdayThis biotech is on a roller coaster that's not uncommon for the sector.
Aug 20, 2015 by Brian Orelli, PhDNew Skin Cancer Drugs Delayed (but Investors and Patients Needn't Worry)FDA decisions for Bristol-Myers Sqibb's Opdivo and Merck's Keytruda get pushed back.
